First-line treatment for her2-positive breast cancer
Part of Cancer, Skin clinical trials.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be HER2-positive (a test shows high levels of the HER2 protein).
- You have not had chemotherapy or HER2-targeted therapy for advanced breast cancer, but you may have had up to one line of hormone therapy.
- You are able to do normal daily activities (ECOG 0-1).
- You have at least one tumor that can be measured on a scan.
- If you have brain metastases, they must be stable or not causing symptoms that need immediate treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.